ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis

FRA:ZEG • GB0009895292

160.7 EUR
+0.95 (+0.59%)
Last: Feb 5, 2026, 07:00 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to ZEG. ZEG was compared to 52 industry peers in the Pharmaceuticals industry. While ZEG belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. ZEG has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year ZEG was profitable.
  • In the past year ZEG had a positive cash flow from operations.
  • Each year in the past 5 years ZEG has been profitable.
  • ZEG had a positive operating cash flow in each of the past 5 years.
ZEG.DE Yearly Net Income VS EBIT VS OCF VS FCFZEG.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

1.2 Ratios

  • With a decent Return On Assets value of 8.96%, ZEG is doing good in the industry, outperforming 63.64% of the companies in the same industry.
  • ZEG's Return On Equity of 21.01% is fine compared to the rest of the industry. ZEG outperforms 65.45% of its industry peers.
  • ZEG's Return On Invested Capital of 13.63% is fine compared to the rest of the industry. ZEG outperforms 65.45% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for ZEG is in line with the industry average of 14.45%.
  • The 3 year average ROIC (12.48%) for ZEG is below the current ROIC(13.63%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 8.96%
ROE 21.01%
ROIC 13.63%
ROA(3y)7.2%
ROA(5y)5.03%
ROE(3y)17.82%
ROE(5y)12.53%
ROIC(3y)12.48%
ROIC(5y)10.5%
ZEG.DE Yearly ROA, ROE, ROICZEG.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20

1.3 Margins

  • Looking at the Profit Margin, with a value of 17.41%, ZEG is in the better half of the industry, outperforming 69.09% of the companies in the same industry.
  • In the last couple of years the Profit Margin of ZEG has grown nicely.
  • ZEG's Operating Margin of 23.86% is in line compared to the rest of the industry. ZEG outperforms 58.18% of its industry peers.
  • In the last couple of years the Operating Margin of ZEG has grown nicely.
  • ZEG has a better Gross Margin (81.31%) than 85.45% of its industry peers.
  • ZEG's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 23.86%
PM (TTM) 17.41%
GM 81.31%
OM growth 3Y6.24%
OM growth 5Y7.63%
PM growth 3Y32.91%
PM growth 5Y7.71%
GM growth 3Y0.34%
GM growth 5Y0.28%
ZEG.DE Yearly Profit, Operating, Gross MarginsZEG.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

4

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ZEG is still creating some value.
  • Compared to 1 year ago, ZEG has about the same amount of shares outstanding.
  • Compared to 5 years ago, ZEG has more shares outstanding
  • ZEG has a better debt/assets ratio than last year.
ZEG.DE Yearly Shares OutstandingZEG.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B
ZEG.DE Yearly Total Debt VS Total AssetsZEG.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

2.2 Solvency

  • ZEG has an Altman-Z score of 3.77. This indicates that ZEG is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of ZEG (3.77) is comparable to the rest of the industry.
  • The Debt to FCF ratio of ZEG is 3.42, which is a good value as it means it would take ZEG, 3.42 years of fcf income to pay off all of its debts.
  • ZEG has a Debt to FCF ratio of 3.42. This is in the better half of the industry: ZEG outperforms 63.64% of its industry peers.
  • A Debt/Equity ratio of 0.55 indicates that ZEG is somewhat dependend on debt financing.
  • ZEG has a Debt to Equity ratio of 0.55. This is in the better half of the industry: ZEG outperforms 61.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.42
Altman-Z 3.77
ROIC/WACC1.49
WACC9.14%
ZEG.DE Yearly LT Debt VS Equity VS FCFZEG.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.3 Liquidity

  • ZEG has a Current Ratio of 0.94. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ZEG has a Current ratio of 0.94. This is amonst the worse of the industry: ZEG underperforms 81.82% of its industry peers.
  • A Quick Ratio of 0.72 indicates that ZEG may have some problems paying its short term obligations.
  • ZEG's Quick ratio of 0.72 is on the low side compared to the rest of the industry. ZEG is outperformed by 74.55% of its industry peers.
Industry RankSector Rank
Current Ratio 0.94
Quick Ratio 0.72
ZEG.DE Yearly Current Assets VS Current LiabilitesZEG.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

5

3. Growth

3.1 Past

  • The earnings per share for ZEG have decreased by -1.34% in the last year.
  • Measured over the past years, ZEG shows a quite strong growth in Earnings Per Share. The EPS has been growing by 15.04% on average per year.
  • The Revenue has grown by 8.63% in the past year. This is quite good.
  • Measured over the past years, ZEG shows a quite strong growth in Revenue. The Revenue has been growing by 17.15% on average per year.
EPS 1Y (TTM)-1.34%
EPS 3Y6.74%
EPS 5Y15.04%
EPS Q2Q%-49.28%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y9.82%
Revenue growth 5Y17.15%
Sales Q2Q%4.11%

3.2 Future

  • The Earnings Per Share is expected to grow by 15.20% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 6.82% on average over the next years.
EPS Next Y30.41%
EPS Next 2Y20.69%
EPS Next 3Y17.63%
EPS Next 5Y15.2%
Revenue Next Year6.06%
Revenue Next 2Y5.93%
Revenue Next 3Y6.22%
Revenue Next 5Y6.82%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ZEG.DE Yearly Revenue VS EstimatesZEG.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B
ZEG.DE Yearly EPS VS EstimatesZEG.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 23.53, which indicates a rather expensive current valuation of ZEG.
  • ZEG's Price/Earnings is on the same level as the industry average.
  • Compared to an average S&P500 Price/Earnings ratio of 27.19, ZEG is valued at the same level.
  • ZEG is valuated rather expensively with a Price/Forward Earnings ratio of 18.05.
  • The rest of the industry has a similar Price/Forward Earnings ratio as ZEG.
  • When comparing the Price/Forward Earnings ratio of ZEG to the average of the S&P500 Index (28.06), we can say ZEG is valued slightly cheaper.
Industry RankSector Rank
PE 23.53
Fwd PE 18.05
ZEG.DE Price Earnings VS Forward Price EarningsZEG.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ZEG is on the same level as its industry peers.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ZEG is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 34.09
EV/EBITDA 16.14
ZEG.DE Per share dataZEG.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • ZEG's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of ZEG may justify a higher PE ratio.
  • ZEG's earnings are expected to grow with 17.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.77
PEG (5Y)1.56
EPS Next 2Y20.69%
EPS Next 3Y17.63%

4

5. Dividend

5.1 Amount

  • ZEG has a Yearly Dividend Yield of 1.64%. Purely for dividend investing, there may be better candidates out there.
  • ZEG's Dividend Yield is comparable with the industry average which is at 1.91.
  • ZEG's Dividend Yield is comparable with the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 1.64%

5.2 History

  • The dividend of ZEG has a limited annual growth rate of 3.33%.
Dividend Growth(5Y)3.33%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 48.62% of the earnings are spent on dividend by ZEG. This is a bit on the high side, but may be sustainable.
  • ZEG's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP48.62%
EPS Next 2Y20.69%
EPS Next 3Y17.63%
ZEG.DE Yearly Income VS Free CF VS DividendZEG.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B
ZEG.DE Dividend Payout.ZEG.DE Dividend Payout, showing the Payout Ratio.ZEG.DE Dividend Payout.PayoutRetained Earnings

ASTRAZENECA PLC

FRA:ZEG (2/5/2026, 7:00:00 PM)

160.7

+0.95 (+0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-10
Earnings (Next)04-29
Inst Owners49.17%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap249.13B
Revenue(TTM)58.74B
Net Income(TTM)10.22B
Analysts82.94
Price Target175.52 (9.22%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.64%
Yearly Dividend2.7
Dividend Growth(5Y)3.33%
DP48.62%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-25.37%
Min EPS beat(2)-60.38%
Max EPS beat(2)9.64%
EPS beat(4)2
Avg EPS beat(4)-12.23%
Min EPS beat(4)-60.38%
Max EPS beat(4)9.64%
EPS beat(8)4
Avg EPS beat(8)-5.74%
EPS beat(12)7
Avg EPS beat(12)-2.63%
EPS beat(16)11
Avg EPS beat(16)-0.36%
Revenue beat(2)1
Avg Revenue beat(2)-1.31%
Min Revenue beat(2)-4.83%
Max Revenue beat(2)2.2%
Revenue beat(4)1
Avg Revenue beat(4)-2.92%
Min Revenue beat(4)-5.08%
Max Revenue beat(4)2.2%
Revenue beat(8)4
Avg Revenue beat(8)-0.54%
Revenue beat(12)5
Avg Revenue beat(12)-0.86%
Revenue beat(16)6
Avg Revenue beat(16)-0.78%
PT rev (1m)5.49%
PT rev (3m)12.4%
EPS NQ rev (1m)-1.75%
EPS NQ rev (3m)-1.48%
EPS NY rev (1m)1.58%
EPS NY rev (3m)-0.37%
Revenue NQ rev (1m)-0.41%
Revenue NQ rev (3m)-0.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.59%
Valuation
Industry RankSector Rank
PE 23.53
Fwd PE 18.05
P/S 5.03
P/FCF 34.09
P/OCF 20.28
P/B 6.07
P/tB N/A
EV/EBITDA 16.14
EPS(TTM)6.83
EY4.25%
EPS(NY)8.9
Fwd EY5.54%
FCF(TTM)4.71
FCFY2.93%
OCF(TTM)7.93
OCFY4.93%
SpS31.94
BVpS26.46
TBVpS-5.67
PEG (NY)0.77
PEG (5Y)1.56
Graham Number63.77
Profitability
Industry RankSector Rank
ROA 8.96%
ROE 21.01%
ROCE 16.8%
ROIC 13.63%
ROICexc 14.63%
ROICexgc 59.47%
OM 23.86%
PM (TTM) 17.41%
GM 81.31%
FCFM 14.76%
ROA(3y)7.2%
ROA(5y)5.03%
ROE(3y)17.82%
ROE(5y)12.53%
ROIC(3y)12.48%
ROIC(5y)10.5%
ROICexc(3y)13.49%
ROICexc(5y)11.39%
ROICexgc(3y)81.92%
ROICexgc(5y)83.55%
ROCE(3y)15.36%
ROCE(5y)12.92%
ROICexgc growth 3Y-25.55%
ROICexgc growth 5Y0.81%
ROICexc growth 3Y9.13%
ROICexc growth 5Y9.72%
OM growth 3Y6.24%
OM growth 5Y7.63%
PM growth 3Y32.91%
PM growth 5Y7.71%
GM growth 3Y0.34%
GM growth 5Y0.28%
F-Score7
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.42
Debt/EBITDA 1.36
Cap/Depr 103%
Cap/Sales 10.05%
Interest Coverage 10.65
Cash Conversion 73.79%
Profit Quality 84.79%
Current Ratio 0.94
Quick Ratio 0.72
Altman-Z 3.77
F-Score7
WACC9.14%
ROIC/WACC1.49
Cap/Depr(3y)80.57%
Cap/Depr(5y)64.46%
Cap/Sales(3y)8.93%
Cap/Sales(5y)7.69%
Profit Quality(3y)99.49%
Profit Quality(5y)775.68%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.34%
EPS 3Y6.74%
EPS 5Y15.04%
EPS Q2Q%-49.28%
EPS Next Y30.41%
EPS Next 2Y20.69%
EPS Next 3Y17.63%
EPS Next 5Y15.2%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y9.82%
Revenue growth 5Y17.15%
Sales Q2Q%4.11%
Revenue Next Year6.06%
Revenue Next 2Y5.93%
Revenue Next 3Y6.22%
Revenue Next 5Y6.82%
EBIT growth 1Y10.05%
EBIT growth 3Y16.67%
EBIT growth 5Y26.09%
EBIT Next Year23.4%
EBIT Next 3Y12.45%
EBIT Next 5Y11.39%
FCF growth 1Y19.18%
FCF growth 3Y6.21%
FCF growth 5Y31.64%
OCF growth 1Y22.88%
OCF growth 3Y14.12%
OCF growth 5Y24.88%

ASTRAZENECA PLC / ZEG.DE FAQ

What is the fundamental rating for ZEG stock?

ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE.


What is the valuation status of ASTRAZENECA PLC (ZEG.DE) stock?

ChartMill assigns a valuation rating of 3 / 10 to ASTRAZENECA PLC (ZEG.DE). This can be considered as Overvalued.


What is the profitability of ZEG stock?

ASTRAZENECA PLC (ZEG.DE) has a profitability rating of 7 / 10.


What is the valuation of ASTRAZENECA PLC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ASTRAZENECA PLC (ZEG.DE) is 23.53 and the Price/Book (PB) ratio is 6.07.


Can you provide the expected EPS growth for ZEG stock?

The Earnings per Share (EPS) of ASTRAZENECA PLC (ZEG.DE) is expected to grow by 30.41% in the next year.